Leonard Jason, PhD, professor of psychology and director of the Center for Community Research at DePaul University in Chicago, Illinois, told
Medscape Medical News, "despite the application of a few case definitions, it's still possible that the sample included individuals who have chronic fatigue due to psychiatric reasons. Overall, I think that the sample would need to be more well-characterized in order to draw any conclusions about CFS or ME from this mediation model."
Dr Jason, whose article on adaptive pacing in ME/CFS was among those cited in the current study (
J Human Behav Soc Environ. 2000;3:59-77), added, "The differences found might be due to response biases, the therapies causing people to answer questions about their health differently. However, a more generous interpretation might be that small improvements were obtained for some individuals. But CFS is a very heterogeneous condition, and just because some therapies can help some people a little doesn't mean they're suitable for all or should be seen as sufficient or curative therapies."
Kenneth J. Friedman, PhD, a coauthor of an ME/CFS "
primer" for clinicians and a former associate professor of pharmacology and physiology, New Jersey Medical School, Newark, pointed out another problem that the PACE trial shares with nearly every study done on ME/CFS: All have been conducted on ambulatory patients, leaving out the most severely affected, who are too sick to participate in studies.
"The extent to which the ambulatory population represents the spectrum of CFS patients is really not known," he told
Medscape Medical News. "If you're lying in bed and you can't move your head and you have to speak in whispers, GET therapy is not going to help you, and were you to attempt it, it would most likely kill you."
With regard to the PACE trial, Dr Friedman said, "It does not represent all CFS patients.... Because CFS is so variable, the management must be individualized. Any mandate that this is what you do for all patients, I would be leery of and would oppose. I think that really is the take-home message."
Dr Chalder declined to comment for this story.